Emergent BioSolutions Announces $24M BARDA Modification for CYFENDUS

What Happened Emergent BioSolutions (EBS) announced in an 8-K filed September 1, 2026 that it received Modification No. 21 to its BARDA AV7909 contract, adding $24 million for procurement of additional doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted, formerly AV7909). The modification is effective August 18, 2026; the underlying BARDA AV7909 contract originally became effective September 30, 2016. A press release dated September 1, 2026 was furnished with the filing.

Key Details

• Modification No. 21 increases the BARDA award by $24,000,000 for additional CYFENDUS vaccine doses.
• Modification effective date: August 18, 2026; 8-K filing and press release dated: September 1, 2026.
• The BARDA AV7909 Contract (original contract) became effective September 30, 2016; Modification No. 21 is filed as Exhibit 10.1 (with redactions) and the press release as Exhibit 99.1.
• The 8-K was signed by Richard S. Lindahl, Executive VP & Chief Financial Officer.

Why It Matters This filing confirms a new, concrete government procurement action that adds $24M of contracted revenue tied to Emergent’s CYFENDUS anthrax vaccine program. For investors, government contract modifications are direct signals of demand and near-term revenue recognition potential tied to public health preparedness programs; the filing also provides official documentation (contract modification and press release) for verification. This is an operational update rather than an earnings report, so investors should watch subsequent financial disclosures for how and when revenue from this modification is recognized.